PCSK9 inhibitors for treatment of high cholesterol: effectiveness, value, and value-based price benchmarks : final report
- Author(s):
- Tice, Jeffrey A., author Ollendorf, Daniel A., author Cunningham, Courtney, author Pearson, Steven D., author Kazi, Dhruv S., author Coxson, Pamela G., author Moran, Andrew E., author Penko, Joanne, author Guzman, David, author Bibbins-Domingo, Kirsten, author
- Contributor(s):
- Institute for Clinical and Economic Review, issuing body. New England Comparative Effectiveness Public Advisory Council, issuing body.
- Publication:
- [Boston, MA] : Institute for Clinical and Economic Review, November 24, 2015
- Language(s):
- English
- Format:
- Text
- Subject(s):
- Anticholesteremic Agents -- therapeutic use Azetidines -- therapeutic use Enzyme Inhibitors -- therapeutic use Hypercholesterolemia -- therapy Hyperlipoproteinemia Type II -- prevention & control Proprotein Convertases -- economics Serine Endopeptidases -- economics Cholesterol, LDL Cost-Benefit Analysis Decision Support Techniques Drug Costs Drug Resistance Practice Guidelines as Topic Randomized Controlled Trials as Topic Technology Assessment, Biomedical Treatment Outcome Value-Based Purchasing Humans New England United States
- Genre(s):
- Technical Report
- Abstract:
- Background. The goal of this report is to address the key issues that patients, providers, and payers face when making decisions about PCSK9 inhibitor therapy and to support the dialogue needed for successful action to improve the quality and value of health care for all patients. The scope for this assessment utilizes the PICOTS (Population, Intervention, Comparators, Outcomes, Timing, and Settings) framework. The evidence review is based on 25 clinical trials and two published systematic reviews and meta-analyses. The results were cross-checked with the manufacturers' FDA submission documents and the FDA's briefing documents. Topic in Context. In summarizing the contextual considerations for appraisal of a health care intervention, we seek to highlight the four following specific issues: (1) Is there a particularly high burden/severity of illness? (2) Do other acceptable treatments exist? (3) Are other, equally or more effective treatments nearing introduction into practice? (4) Would other societal values accord substantially more or less priority to providing access to this treatment for this patient population?
- Copyright:
- Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license. (More information)
- Extent:
- 1 online resource (1 PDF file (i-v, ES 1-ES 18, 115 pages))
- Illustrations:
- Illustrations
- NLM Unique ID:
- 101672684 (See catalog record)
- Permanent Link:
- http://resource.nlm.nih.gov/101672684